Related references
Note: Only part of the references are listed.Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women
Barbara J. Jefferis et al.
ATHEROSCLEROSIS (2010)
Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer
Takaki Yoshikawa et al.
GASTRIC CANCER (2009)
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood
Klaus Jung
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study
Malcolm J. West et al.
EUROPEAN HEART JOURNAL (2008)
Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality
S. Frantz et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer
Zheng-Sheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Risk Factors in a Middle-Aged Normal Population
Peter Garvin et al.
PLOS ONE (2008)
Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men
Anita M. Tuomainen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer
Norio Yukawa et al.
ONCOLOGY (2007)
Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis
Nikolaj Eldrup et al.
CIRCULATION (2006)
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction
Erdal Cavusoglu et al.
AMERICAN HEART JOURNAL (2006)
Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events
Johan Sundstrom et al.
CURRENT OPINION IN LIPIDOLOGY (2006)
Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study
E Lubos et al.
EUROPEAN HEART JOURNAL (2006)
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
J George et al.
AMERICAN HEART JOURNAL (2005)
Calculating measures of biological interaction
T Andersson et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2005)
Plasma storage at-80°C does not protect matrix metalloproteinase-9 from degradation
D Rouy et al.
ANALYTICAL BIOCHEMISTRY (2005)
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth
A Luttun et al.
CIRCULATION (2004)
Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures:: the Framingham heart study
J Sundström et al.
EUROPEAN HEART JOURNAL (2004)
Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures -: The Framingham Heart Study
J Sundström et al.
CIRCULATION (2004)
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease
S Blankenberg et al.
CIRCULATION (2003)
The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?
MG Belvisi et al.
INFLAMMATION RESEARCH (2003)
Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
J Montaner et al.
CIRCULATION (2003)
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice
EEJM Creemers et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke
M Castellanos et al.
STROKE (2003)
Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene
J Montaner et al.
STROKE (2003)
Metalloproteinases in development and progression of vascular disease
HR Lijnen
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer
MP Turunen et al.
MOLECULAR THERAPY (2002)
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene
J Silence et al.
CIRCULATION RESEARCH (2002)
Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload
AL Chancey et al.
CIRCULATION (2002)
Matrix metalloproteinase expression after human cardioembolic stroke -: Temporal profile and relation to neurological impairment
J Montaner et al.
STROKE (2001)
Share Paper
